Inflammatory bowel disease in 2024 and beyond DOI Open Access
Richard B. Gearry, Cynthia H. Seow, Sreedhar Subramanian

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1164 - 1165

Опубликована: Окт. 15, 2024

In 1987, Professor Roy Pounder launched Alimentary Pharmacology and Therapeutics in that very issue, he was the senior author on a retrospective study of cyclosporin for management Crohn's disease.1 Since time, incidence prevalence inflammatory bowel disease (IBD) has risen exponentially, reaching all corners globe ethnicities. provided gastroenterologists with broad spectrum clinically relevant journal articles 37 years through 60 volumes high-quality publications. The breadth these is reflected range we have assembled this special IBD edition Therapeutics. Looking back listings, ninth focused IBD, but first 16 years. As associate editors, are proud collection cutting-edge reviews written by an exceptional group experts, strong connections to journal. possibility prevention would seemed fanciful. However, as learn from trials type 1 diabetes mellitus rheumatoid arthritis, several critical steps emerged need be followed if advance prediction prevention. Bronze et al. present road map how can navigate journey via validated predictive biomarkers develop multi-dimensional tool. While science advances, must also aware ethical issues including preferences first-degree relatives those use information. Finally, bringing together expertise patients high-risk clinics should enable appropriate trials.2 question what comprises severe been one long vexed clinicians IBD. Over interest moved symptoms both markers inflammation (endoscopic, histologic biomarkers) more holistic view (quality life, disability psychosocial health). Swaminathan walk us concepts before defining severity includes facets Understanding interact enables focus specific therapeutic targets improve outcomes individuals IBD.3 wider burden gut–brain axis Riggott describe bi-directional relationship between psychological wellbeing adverse longitudinal activity outcomes, high irritable syndrome-type symptoms. Treatments target include behavioural treatments, neuromodulators dietary interventions. Proactive health component overall patients.4 their review evidence-based Gibson four pillars management. This paradigm provides excellent approach strategies Firstly, nutritional status optimized accurate body composition measurement attention sarcopenia visceral adiposity. Secondly, exclusive enteral nutrition exclusion diet partial effective at reducing intestinal disease. Thirdly, there approaches managing non-inflammatory following healthy fundamental general There clear risks inadequacy maladaptive eating behaviours.5 For than 25 used biologic drugs treatment time number increased now scope, our ability each smarter led benefits patients. Chaemsupaphan using drug monitoring neutralizing antibodies. Optimizing effect increases likelihood clinical deeper levels remission treat-to-target paradigm. guidelines when escalate switch agents anti-TNF drugs, non-TNF inhibitors demonstrate less robust exposure-response relationships may not prove beneficial.6 final paper edition, Noor provide pragmatic guide recently approved emerging therapies address key challenges optimal sequencing timing treatment. many new therapies, further data term extension studies, real world studies head-to-head needed inform safety strategies.7 We like thank 24 authors eight countries contributing hope you will enjoy reading thoughtful papers other work published future. Richard B. Gearry: Conceptualization; writing – original draft; editing; visualization; project administration. Cynthia H. Seow: Sreedhar Subramanian: R.B.G. received research grants, served advisory boards or honoraria educational activities Janssen, AbbVie Zespri (unrelated manuscript). C.H.S AbbVie, Takeda, Lilly, Ferring, Shire, Pfizer, Sandoz, Pharmascience, Fresenius Kabi Amgen, Bristol Myers Squibb, ACHRI, CIHR, Calgary Health Trust, New South Wales Government Health. S.S. MSD, Ipsen, Dr. Falk pharmaceuticals, Celltrion Vifor pharmacceuticals. Data sharing applicable article no were created analyzed study.

Язык: Английский

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications DOI
Christy Riggott, Alexander C. Ford, David J. Gracie

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1200 - 1214

Опубликована: Окт. 5, 2024

Summary Background Treatments targeting the gut–brain axis (GBA) are effective at reducing symptom burden in irritable bowel syndrome (IBS). The prevalence of common mental disorders and IBS‐type reporting is significantly higher inflammatory disease (IBD) than would be expected, suggesting potential GBA effects this setting. Manipulation may offer novel treatment strategies selected patients with IBD. We present a narrative review bi‐directional IBD explore for GBA‐targeted therapies Methods searched MEDLINE, EMBASE, EMBASE Classic, PsychINFO, Cochrane Central Register Controlled Trials relevant articles published by March 2024. Results relationship between psychological well‐being adverse longitudinal activity outcomes, high highlight presence GBA‐mediated interactions including brain–gut behavioural treatments, neuromodulators, dietary interventions appear to useful adjunctive treatments subset patients. Conclusions Psychological morbidity prevalent reporting, poor health mediated via GBA. Proactive management should integrated into routine care. Further clinical trials therapies, conducted groups co‐existent disorders, or those who report symptoms, required inform models care future.

Язык: Английский

Процитировано

15
Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target DOI Creative Commons
Akhilesh Swaminathan, Andrew S. Day, Miles Sparrow

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1176 - 1199

Опубликована: Окт. 15, 2024

Summary Background Inflammatory bowel disease (IBD) follows a heterogenous course and predicting patient's prognosis is challenging. There wide burden of illness in IBD existing tools measure activity at snapshot time. Comprehensive assessment severity should incorporate activity, prognosis, the impacts on patient. This review investigates concept adults with to highlight key components contributing this. Methods To perform this narrative review, Medline search was conducted for full‐text articles available 1st March 2024 using terms which encompassed assessment, severity, natural history Crohn's (CD) ulcerative colitis (UC), IBD. Results Current methods have evolved from focus symptoms one that includes inflammatory targets, genetic, serological, proteomic profiles, assessments quality‐of‐life (QoL), disability, psychosocial health. Longitudinal studies suggest driven by phenotype, clinical markers complicated (previous intestinal resection, corticosteroid use, perianal CD, recent hospitalisations UC), gut inflammation, impact Conclusions Disease can be difficult conceptualise due multitude factors contribute outcomes. Measurement may better encapsulate full rather than inflammation alone single timepoint associated longitudinal

Язык: Английский

Процитировано

13
Review article: Evidence‐based dietary management of inflammatory bowel disease DOI Creative Commons
Peter R. Gibson, Chu K Yao, Emma P. Halmos

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1215 - 1233

Опубликована: Авг. 20, 2024

Summary Background Dietary management of patients with inflammatory bowel disease (IBD) involves more than defining a therapeutic diet. The profusion ‘expert advice’ is not necessarily built on evidence. Aims To provide evidence‐based guidance all clinically relevant aspects nutritional and dietary IBD. Methods A comprehensive review the published literature was made. Results Four pillars should be considered in patients. First, status optimised, since myopenia visceral obesity are associated poorer outcomes, which can improved attention to their correction. Accurate point‐of‐care measurement body composition advocated identify problems, guide interventions monitor outcomes. Second, exclusive enteral nutrition Crohn's Disease Exclusion Diet partial reducing intestinal inflammation have sufficient evidence advocated. Multiple other approaches, while promising, insufficient recommended. Third, approaches important symptomatic control many non‐inflammatory scenarios. Finally, following healthy diet fundamental general health advocated, but optimal strategy unclear. precarious IBD together risks inadequacy maladaptive eating behaviours restrictive diets dictate involvement expert dietitians assessment personalised delivery interventions. Conclusions require specific interventional strategies that chosen by Optimal requires skills specialised dietitian.

Язык: Английский

Процитировано

9
Review article: Prevention of inflammatory bowel disease—The path forward DOI
Sérgio Bronze, Manasi Agrawal, Jean‐Frédéric Colombel

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1166 - 1175

Опубликована: Окт. 15, 2024

Summary Background The possibility of preventing inflammatory bowel disease (IBD) is becoming more plausible due to advances in understanding preclinical and successful prevention trials other immune‐mediated diseases, such as type 1 diabetes rheumatoid arthritis. However, before that becomes reality, several efforts need occur parallel a coordinated way. Aim To propose some critical steps necessary for advancing the field IBD prediction prevention. Methods We reviewed current literature identify toward preventive strategy IBD. Results first step should determine most robust predictive biomarkers validate them across independent cohorts, creating multidimensional tool. second gain better preferences first‐degree relatives people at risk IBD, informing implementation screening strategies. Third, these contribute development high‐risk clinics establish networks trials. Conclusions Advancing will require multifaceted approach, integrating biomarker discovery, patient preferences, establishing infrastructure collaborative network support practical

Язык: Английский

Процитировано

9
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease DOI Creative Commons
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1234 - 1243

Опубликована: Окт. 15, 2024

Summary Background There are a plethora of therapeutic options for the management inflammatory bowel disease (IBD). Despite this, clinical outcomes with standard dosing often fall short established targets. While efforts centre on developing novel therapies, there is an ongoing need to optimise use existing agents. Aims To focus strategies response biologic (monoclonal antibody) therapies in IBD, including drug monitoring (TDM). Methods An extensive review published literature. Results TDM strategy aimed at enhancing effectiveness drugs variable exposure‐response relationships by measuring serum concentrations and detecting neutralising antibodies. Reactive performed when goals have not been achieved. Tumour necrosis factor alpha (TNF) inhibitors treatment class most frequently associated immunogenicity loss response. Immunogenicity can be reduced through avoidance low dose optimisation or concomitant immunomodulator therapy. Subtherapeutic absence antidrug antibodies best managed escalation interval reduction. Persistent necessitate switching alternative Proactively ensuring adequate trough levels might help sustain durability prevent Newer non‐TNF demonstrate less robust relationships, may prove as beneficial. Conclusions In treat‐to‐target paradigm IBD treatment, optimising effect optimisation, which involve TDM, increases likelihood achieving remission accomplish deeper beyond symptom control.

Язык: Английский

Процитировано

8
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years DOI Creative Commons
Jian Wan, Jiaming Zhou, Zhuo Wang

и другие.

Chinese Medical Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 25, 2025

Abstract Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic inflammation of the gastrointestinal tract with unknown etiology. The cause IBD widely considered multifactorial, prevailing hypotheses suggesting that microbiome various environmental factors contribute to inappropriate activation mucosal immune system in genetically susceptible individuals. Although incidence has stabilized Western countries, it rapidly increasing newly industrialized particularly China, making global disease. Significant changes multiple biomarkers before diagnosis during preclinical phase provide opportunities for earlier intervention. Advances technology have driven development telemonitoring tools, such as home-testing kits fecal calprotectin, serum cytokines, therapeutic drug concentrations, well wearable devices testing sweat cytokines heart rate variability. These tools enable real-time activity assessment timely treatment strategy adjustments. A wide range novel drugs IBD, interleukin-23 inhibitors (mirikizumab, risankizumab, guselkumab) small-molecule (etrasimod upadacitinib), been introduced past few years. Despite these advancements, approximately one-third patients remain primary non-responders initial treatment, half eventually lose response over time. Precision medicine integrating multi-omics data, advanced combination therapy, complementary approaches, stem cell transplantation, psychological therapies, neuromodulation, gut modulation may offer solutions break through ceiling.

Язык: Английский

Процитировано

1
Biochanin A Mitigates Colitis by Inhibiting Ferroptosis-Mediated Intestinal Barrier Dysfunction, Oxidative Stress, and Inflammation via the JAK2/STAT3 Signaling Pathway DOI

Beiying Deng,

Kunpeng Wang, Haodong He

и другие.

Phytomedicine, Год журнала: 2025, Номер unknown, С. 156699 - 156699

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International Survey DOI Open Access
Mohmmed Tauseef Sharip, Biljana Brezina,

Juan De La Revilla Negro

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(3), С. 667 - 667

Опубликована: Янв. 21, 2025

Background/Objectives: The management of inflammatory bowel disease (IBD) varies due to differences in healthcare systems, treatment costs, access diagnostics, and diverse clinical practices between specialists. Despite the frequent advocacy a treat-to-target (T2T) approach, there is insufficient clarity on how clinicians implement T2T real-world settings. We aim conduct large, global survey among IBD experts identify current management. Methods: A prospective, cross-sectional study was conducted using 16-item divided into two sections—for ulcerative colitis (UC) Crohn’s (CD)—and distributed practicing clinicians. Results: total 261 respondents from 88 countries participated survey, with majority (253/261) being physicians eight nurse guidance, only quarter routinely perform an endoscopy assess response after starting advanced therapy (28.4% UC vs. 23.5% CD). Moreover, despite increasing academic focus intestinal ultrasound (IUS), 171 (66%) 132 (51%) CD reported that they do not undertake IUS guide decisions. Faecal calprotectin for monitoring used by 87% (90% 84% CD) respondents. Forty-five percent use therapeutic drug (TDM) both proactively reactively 35% TDM reactively. Conclusions: Our shows considerable variation across different interpretation approach. This highlights need standardised pragmatic guidelines help improve outcomes patients globally.

Язык: Английский

Процитировано

0
Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis DOI Open Access
Benedetto Neri, Roberto Mancone,

Mariasofia Fiorillo

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7186 - 7186

Опубликована: Ноя. 27, 2024

Background: Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (UC); therefore, further information is needed, particularly regarding efficacy and safety. Objectives: To provide a comprehensive review the safety of currently available JAK-i in UC. Methods: The PubMed Scopus databases were considered, searching ‘JAK’, ‘JAK-inhibitor’, ‘Janus Kinases’, ‘Tofacitinib’, ‘Filgotinib’, ‘Upadacitinib’, individually or combination ‘IBD’, ‘Ulcerative Colitis’, ‘safety’, ‘efficacy’, ‘study’ ‘trial’. search was focused on full-text papers published English, no publication date restrictions. Results: UC summarized. These included Tofacitinib, Filgotinib Upadacitinib. Findings from both clinical trials real-life studies reported, particular regard to their inducing response remission, steroid-free remission endoscopic histological healing. Overall, proved be effective safe selected subgroups rapid onset action oral route administration represent most relevant characteristics these drugs. Safety concerns using Tofacitinib (infections, hypercholesterolemia, venous thromboembolism cardiovascular events) initially raised. More recently, all showed an overall satisfactory profile. However, indication should carefully given. Conclusions: use promising, although predictive markers are available. Optimizing use, as monotherapy combined other immunomodulators, may increase appropriately

Язык: Английский

Процитировано

3
Inflammatory bowel disease in 2024 and beyond DOI Open Access
Richard B. Gearry, Cynthia H. Seow, Sreedhar Subramanian

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(9), С. 1164 - 1165

Опубликована: Окт. 15, 2024

In 1987, Professor Roy Pounder launched Alimentary Pharmacology and Therapeutics in that very issue, he was the senior author on a retrospective study of cyclosporin for management Crohn's disease.1 Since time, incidence prevalence inflammatory bowel disease (IBD) has risen exponentially, reaching all corners globe ethnicities. provided gastroenterologists with broad spectrum clinically relevant journal articles 37 years through 60 volumes high-quality publications. The breadth these is reflected range we have assembled this special IBD edition Therapeutics. Looking back listings, ninth focused IBD, but first 16 years. As associate editors, are proud collection cutting-edge reviews written by an exceptional group experts, strong connections to journal. possibility prevention would seemed fanciful. However, as learn from trials type 1 diabetes mellitus rheumatoid arthritis, several critical steps emerged need be followed if advance prediction prevention. Bronze et al. present road map how can navigate journey via validated predictive biomarkers develop multi-dimensional tool. While science advances, must also aware ethical issues including preferences first-degree relatives those use information. Finally, bringing together expertise patients high-risk clinics should enable appropriate trials.2 question what comprises severe been one long vexed clinicians IBD. Over interest moved symptoms both markers inflammation (endoscopic, histologic biomarkers) more holistic view (quality life, disability psychosocial health). Swaminathan walk us concepts before defining severity includes facets Understanding interact enables focus specific therapeutic targets improve outcomes individuals IBD.3 wider burden gut–brain axis Riggott describe bi-directional relationship between psychological wellbeing adverse longitudinal activity outcomes, high irritable syndrome-type symptoms. Treatments target include behavioural treatments, neuromodulators dietary interventions. Proactive health component overall patients.4 their review evidence-based Gibson four pillars management. This paradigm provides excellent approach strategies Firstly, nutritional status optimized accurate body composition measurement attention sarcopenia visceral adiposity. Secondly, exclusive enteral nutrition exclusion diet partial effective at reducing intestinal disease. Thirdly, there approaches managing non-inflammatory following healthy fundamental general There clear risks inadequacy maladaptive eating behaviours.5 For than 25 used biologic drugs treatment time number increased now scope, our ability each smarter led benefits patients. Chaemsupaphan using drug monitoring neutralizing antibodies. Optimizing effect increases likelihood clinical deeper levels remission treat-to-target paradigm. guidelines when escalate switch agents anti-TNF drugs, non-TNF inhibitors demonstrate less robust exposure-response relationships may not prove beneficial.6 final paper edition, Noor provide pragmatic guide recently approved emerging therapies address key challenges optimal sequencing timing treatment. many new therapies, further data term extension studies, real world studies head-to-head needed inform safety strategies.7 We like thank 24 authors eight countries contributing hope you will enjoy reading thoughtful papers other work published future. Richard B. Gearry: Conceptualization; writing – original draft; editing; visualization; project administration. Cynthia H. Seow: Sreedhar Subramanian: R.B.G. received research grants, served advisory boards or honoraria educational activities Janssen, AbbVie Zespri (unrelated manuscript). C.H.S AbbVie, Takeda, Lilly, Ferring, Shire, Pfizer, Sandoz, Pharmascience, Fresenius Kabi Amgen, Bristol Myers Squibb, ACHRI, CIHR, Calgary Health Trust, New South Wales Government Health. S.S. MSD, Ipsen, Dr. Falk pharmaceuticals, Celltrion Vifor pharmacceuticals. Data sharing applicable article no were created analyzed study.

Язык: Английский

Процитировано

0